The latest headlines across every section, pulled from official and open-access sources.
AbbVie has struck a deal to buy Apogee Therapeutics for $10.9 billion. The deal will give AbbVie control of a late-phase eczema drug candidate that could pose a threat to Eli Lilly, Regeneron and Sanofi.
French biopharma Sanofi inked a partnership deal with Pangaea Data to use its AI platform that helps detect Alpha-1 Antitrypsin Deficiency (AATD) that will be distributed to select healthcare systems and low-income community care clinics.
Merck is making advances in the lucrative ulcerative colitis field with the key prize of its $11 billion buyout from several years ago.
In another sign that the FDA is easing its stance toward rare disease drug candidates under new leadership, the agency will reconsider Regenxbio’s gene therapy for an ultra-rare childhood disease, a reversal coming just about four months after a rejection.
Virtual control groups are redefining study design—cutting animal use while advancing rigor and regulatory momentum.
As the biotech world flocks to San Diego today for the BIO International Convention, the Department of Health and Human Services has provided plenty of conversation fodder with the announcement of a series of efforts to regain ground on China’s surging early-stage clinical development capabilities.
Exelixis’ next franchise drug, zanzalintinib, has hit a clinical setback, although at least two groups of analysts suggested that an FDA approval is still on the table.
Pfizer announced Monday that sigvotatug vedotin, the first new ADC to read out pivotal data following its $43 billion acquisition of Seagen, has stumbled in a phase 3 study in non-small cell lung cancer.
The FDA has sent out an early alert to J&J’s Abiomed unit and its manufacturing partner Oscor for their catheter introducer kits that are used with Impella heart pumps amid manufacturing concerns.
With a balance of competitive efficacy and tolerability, Corxel figures it has a potential winner to take into late-stage development.
While dealmaking and investment dollars may be flowing across biopharma once again, acute challenges tied to policy, pricing and more continue to dog the industry, even as pipelines bring massive sales opportunities to bear.
Merck KGaA has committed $50 million to build a new biotech with prolific life science investor Versant Ventures, with the ultimate goal of devouring the NewCo down the line.